17:54 , Nov 1, 2017 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: October 2017

New Therapeutic Targets and Biomarkers: October 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during October 2017. Therapeutic targets are defined as any protein, gene or other molecule...
20:10 , Oct 25, 2017 |  BC Extra  |  Preclinical News

Harvard researchers report new base editor tool

In a paper published in Nature, a team of Harvard University and Broad Institute of MIT and Harvard researchers led by David Liu described its latest iteration of the base editor gene editing tool. The...
21:45 , Jun 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Pumping iron

A natural compound from the Japanese Hinoki tree may hold the answer to iron transport diseases treated inadequately by phlebotomy, chelation therapy or dietary supplements. In Science last month, a University of Illinois-led group reported...
19:40 , Apr 14, 2017 |  BC Week In Review  |  Clinical News

Personal Genome Service Genetic Health Risk (GHR) test regulatory update

FDA approved 23andMe's PGS Genetic Health Risk (GHR) test to assess genetic risk for 10 diseases and conditions. The approved indications are Parkinson’s disease (PD), late-onset Alzheimer’s disease (AD), celiac disease, alpha-1 antitrypsin (AAT; A1AT;...
19:59 , Dec 13, 2016 |  BC Innovations  |  Distillery Therapeutics

Hematology

INDICATION: Hematology Mouse studies suggest an NGAL-enterobactin complex could help treat iron overload caused by chronic blood transfusion, hemochromatosis and other disorders. The complex consisted of the iron-chelating molecule enterobactin bound to a human NGAL variant...
07:00 , Sep 19, 2016 |  BC Week In Review  |  Clinical News

LJPC-401: Phase I data

An open-label, dose-escalation Phase I trial in 15 patients at risk of iron overload showed that single doses of 1-20 mg subcutaneous LJPC-401 dose-dependently and significantly reduced mean serum iron levels from baseline to 8...
08:00 , Nov 9, 2015 |  BC Week In Review  |  Clinical News

LJPC-401: Phase I started

La Jolla began an open-label, dose-escalation Phase I trial to evaluate LJPC-401 in patients at risk of iron overload due to conditions such as hereditary hemochromatosis, beta thalassemia and sickle cell disease (SCD). La Jolla...
07:00 , Sep 8, 2014 |  BC Week In Review  |  Clinical News

Ferric citrate regulatory update

FDA approved an NDA from Keryx for ferric citrate to treat hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. FDA contraindicated the drug in patients with iron overload syndromes such as hemochromatosis. The...
01:21 , Sep 6, 2014 |  BC Extra  |  Company News

FDA approves Keryx's ferric citrate

FDA approved ferric citrate from Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) to treat hyperphosphatemia in dialysis-dependent patients with chronic kidney disease (CKD). FDA contraindicated the drug in patients with iron overload syndromes such as hemochromatosis. Keryx has...
07:00 , May 14, 2012 |  BioCentury  |  Strategy

Teva: No more silos

Teva Pharmaceutical Industries Ltd.'s new CSO and president of global R&D, Michael Hayden, plans to break down the silos housing generics and branded R&D with the aim of improving both businesses while better serving a...